BetterLife Pharma BETR.CN · CAD

Its shares trade on Canadian Securities Exchange under the ticker BETR.CN. It has been listed since 19 December 2017.

BetterLife Pharma, Inc. is an early stage pharmaceutical company, which engages in the development and commercialization of therapeutic pharmaceutical and nutraceutical products. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2017-12-19. The firm is engaged in the development and commercialization of nutraceuticals and pharmaceuticals. Its products include AP-001, AP-002 and AP-003. AP-001 is a topical formulation of recombinant human Intensified high-dose intravenous interferon alpha 2b (IFNa2b) based on its Biphasix drug formulation technology. The Biphasix formulation allows stable cream formulation of IFNa2b and its delivery across the dermis/mucosa, with minimal systemic exposure. AP-001 is developed to treat human papillomavirus (HPV) induced cervical intraepithelial neoplasia (CIN). AP-002 is an organo-gallium complex whose drug substance is tris (8-quinolinolato) gallium (III). AP-002 has direct anti-tumor activity as well as direct anti-osteoclast activity. AP-003 is an IFNa2b inhalation formulation. The firm is also engaged in developing psychedelic compounds, peptides, pro-drugs and nutraceuticals.

Figures and description from our data supplier, not checked against the company's own report.

• Dr. Ahmad DoroudianChairman of the Board, Chief Executive Officer, since 2007C$523,154
• Ms. Moira OngChief Financial OfficerC$517,010
• Dr. Hooshmand SheshbaradaranChief Operating OfficerC$589,983
• Dr. Steven SanghaDirector
• Mr. Robert MetcalfeIndependent DirectorC$104,297
• Mr. Ralph PullenIndependent DirectorC$119,438
• Dr. Wolfgang RenzIndependent Director, since 2015C$36,163

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.